Dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors (investigational metabolic peptide)
Survodutide
Investigationalaka BI 456906
Survodutide is an experimental single-molecule dual agonist of the GLP-1 and glucagon receptors studied for chronic weight management and for MASH (formerly NASH). A published Phase 2 trial in MASH reported improvements in liver histology, and Phase 2 obesity data showed substantial weight reductions; a Phase 3 program (SYNCHRONIZE) is ongoing. It remains investigational and is not authorized for clinical use.
Compare
Mechanism
In plain terms, survodutide mimics two hormones at once to reduce appetite and influence how the liver and body handle fat and sugar. Technically, it is a synthetic peptide that simultaneously agonizes the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. GLP-1 activity promotes satiety and glucose-dependent insulin secretion, while glucagon-receptor agonism is thought to increase energy expenditure and hepatic lipid metabolism, a combination proposed to drive weight loss and reduce liver fat.
Regulatory Status by Region
- United States (FDA)Investigational; not approved. Being evaluated in a Phase 3 program (SYNCHRONIZE) for obesity, with additional trials in MASH.
- Australia (TGA)Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
- European Union (EMA)Not authorized; investigational, no marketing authorization.
- WADANot listed on the WADA Prohibited List. As an investigational incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.
Key Studies
Related Clinical Trials
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightPhase 3 · Not Yet Recruiting
- SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightPhase 3 · Not Yet Recruiting
- ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseasePhase 3 · Not Yet Recruiting
- A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityPhase 1 · Recruiting
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarPhase 3 · Recruiting
- A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyPhase 1 · Active Not Recruiting
- A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorPhase 1 · Completed
- Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseasePhase 2 · Not Yet Recruiting
Related News & Research
- Phase 3 SYNCHRONIZE-2 Trial of Survodutide Published in NEJM, Shows Weight and Blood Sugar Improvements in Type 2 Diabetes
- This Week in Peptide Research: Survodutide's Phase 3 Obesity Data, Mazdutide's US Phase 2 Trial, and a Bone-Peptide Cluster
- This Week in Peptide Research: A Kisspeptin Reproductive-Axis Cluster, Survodutide's Liver Mechanism, and Teriparatide's Cost Question
Latest research
- Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease? (opens in a new tab)
Diabetes, obesity & metabolism · Oct 12, 2026
- Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties. (opens in a new tab)
Contemporary clinical trials · Oct 2, 2026
- Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease. (opens in a new tab)
Diabetes, obesity & metabolism · Oct 1, 2026
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. (opens in a new tab)
The New England journal of medicine · Oct 1, 2026
Common Questions
- What is Survodutide?
- Survodutide is an investigational once-weekly GLP-1/glucagon dual receptor agonist being developed by Boehringer Ingelheim and Zealand Pharma for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is not approved by any regulator as of 2026; it is being evaluated in Phase 3 trials.
- Is Survodutide approved for medical use?
- Survodutide is investigational: it is being studied in clinical research and is not an approved medicine. United States (FDA): Investigational; not approved. Being evaluated in a Phase 3 program (SYNCHRONIZE) for obesity, with additional trials in MASH. European Union (EMA): Not authorized; investigational, no marketing authorization. Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
- How does Survodutide work?
- In plain terms, survodutide mimics two hormones at once to reduce appetite and influence how the liver and body handle fat and sugar. Technically, it is a synthetic peptide that simultaneously agonizes the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.
- Is Survodutide legal in Australia?
- Survodutide in Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
- Is Survodutide banned in sport?
- Survodutide under the World Anti-Doping Agency (WADA) code: Not listed on the WADA Prohibited List. As an investigational incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.